CN117979973A - 作为神经保护剂的释放一氧化氮的前列腺酰胺 - Google Patents

作为神经保护剂的释放一氧化氮的前列腺酰胺 Download PDF

Info

Publication number
CN117979973A
CN117979973A CN202180102507.6A CN202180102507A CN117979973A CN 117979973 A CN117979973 A CN 117979973A CN 202180102507 A CN202180102507 A CN 202180102507A CN 117979973 A CN117979973 A CN 117979973A
Authority
CN
China
Prior art keywords
dihydroxycyclopentyl
hepten
propen
phenylethyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180102507.6A
Other languages
English (en)
Chinese (zh)
Inventor
F·因派纳提洛
E·巴斯蒂亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Original Assignee
Nicox SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox SA filed Critical Nicox SA
Publication of CN117979973A publication Critical patent/CN117979973A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180102507.6A 2021-09-20 2021-09-20 作为神经保护剂的释放一氧化氮的前列腺酰胺 Pending CN117979973A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2021/075786 WO2023041182A1 (en) 2021-09-20 2021-09-20 Nitric oxide releasing prostamide as neuroprotective agent

Publications (1)

Publication Number Publication Date
CN117979973A true CN117979973A (zh) 2024-05-03

Family

ID=77998957

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180102507.6A Pending CN117979973A (zh) 2021-09-20 2021-09-20 作为神经保护剂的释放一氧化氮的前列腺酰胺

Country Status (7)

Country Link
US (1) US20240390390A1 (https=)
EP (1) EP4404936A1 (https=)
JP (1) JP2024533601A (https=)
CN (1) CN117979973A (https=)
CA (1) CA3232002A1 (https=)
TW (1) TW202327617A (https=)
WO (1) WO2023041182A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
AR076731A1 (es) 2008-05-09 2011-07-06 Pfizer Prostamidas donadoras de oxido nitrico, uso de los mismos y composiciones farmaceuticas
US11058691B2 (en) 2016-11-08 2021-07-13 Nicox S.A. Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma
ES2923623T3 (es) 2018-02-21 2022-09-29 Nicox Sa Procedimiento para la preparación de un análogo de prostaglandina donante de óxido nítrico
AU2019300203B2 (en) 2018-07-12 2025-01-30 Nicox S.A. Ophthalmic compositions containing a nitric oxide releasing prostamide

Also Published As

Publication number Publication date
WO2023041182A1 (en) 2023-03-23
TW202327617A (zh) 2023-07-16
JP2024533601A (ja) 2024-09-12
US20240390390A1 (en) 2024-11-28
CA3232002A1 (en) 2023-03-23
EP4404936A1 (en) 2024-07-31

Similar Documents

Publication Publication Date Title
US6242442B1 (en) Brinzolamide and brimonidine for treating ocular conditions
JP2011516537A (ja) 安定性のある眼科用の製剤
KR20100135748A (ko) 아쥬반트로서의 안과용 ｎｓａｉｄ
IL292350A (en) Treatment of ocular diseases using endothelin receptor antagonists
Egorov et al. Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma
Curran Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension
ES2764654T3 (es) Combinaciones de prostaglandinas y donantes de óxido nítrico
US20160151386A1 (en) Sustained release formulations for the treatment of intraocular pressure or glaucoma
US20030007971A1 (en) Remedies for ophthalmic diseases
CN117979973A (zh) 作为神经保护剂的释放一氧化氮的前列腺酰胺
HK40109915A (zh) 作为神经保护剂的释放一氧化氮的前列腺酰胺
KR20230147006A (ko) 무방부제 안과용 약학 에멀젼 및 이의 적용
WO2019065838A1 (ja) ピリジルアミノ酢酸化合物を含有する医薬
CA2398900A1 (en) Therapeutic agents for opthalmopathy
EP4233867B1 (en) Pde5 inhibitor for use in the treatment of anterior ischemic optic neuropathy
Sharpe et al. A comparison of dorzolamide/timolol-fixed combination versus bimatoprost in patients with open-angle glaucoma who are poorly controlled on latanoprost
Kanner et al. Adrenergic Agents
Lodhi et al. Latanoprost 0.005% v/s timolol maleate 0.5% pressure lowering effect in primary open angle glaucoma
WO2025049378A1 (en) Netarsudil ophthalmological formulations with less toxicity
KR20000016784A (ko) 안 순환 장해 개선제
Moster Parul Ichhpujani &
ANGLE BULLETIN OF STOMATOLOGY AND MAXILLO-FACIAL SURGERY OF Vol․ 18, No. 1 Special Issue
Voskanyan et al. BULLETIN OF STOMATOLOGY AND MAXILLO-FACIAL SURGERY
US20120101167A1 (en) Treatment of ocular and cerebral ischemia
Costa et al. 11. MEDICAL THERAPY

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40109915

Country of ref document: HK